ALK’s mission is to improve quality of life by developing pharmaceuticals that treat the actual cause of allergy instead of just relieving symptoms. This remains a responsible way of managing diseases from patient and society perspectives – not least because allergy vaccination potentially prevents the development of additional allergies and asthma.
The amounts of biological and chemical materials used in the production of allergy vaccines are very small, thus affecting the environment at a very low scale compared to most industries. The gradual paradigm shift in general treatment of allergy away from short-range symptomatic treatment towards treament of the actual cause of allergy with allergy vaccines is, however, creating sustained growth in the production of ALK’s allergy vaccines.
As a growth company, ALK recognizes the need to design or adapt corporate processes with a view to reducing environmental impact, increasing employee welfare and contributing positively to the local and national communities.
Even though ALK’s corporate mission and culture create a solid foundation for conducting a responsible and sustainable business, ALK has decided to systematize ongoing CSR activities.